TW200814988A - Therapeutic combination for painful medical conditions - Google Patents

Therapeutic combination for painful medical conditions Download PDF

Info

Publication number: TW200814988A
Authority: TW; Taiwan
Prior art keywords: group; pain; combination; agent; inflammatory
Prior art date: 2006-06-08

Application number

TW096120539A

Other languages

English (en)

Chinese (zh)

Inventor

Bettina Beyreuther

Thomas Stoehr

Original Assignee

Sanol Arznei Schwarz Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-08

Filing date

2007-06-07

Publication date

2008-04-01

2006-08-18 Priority claimed from PCT/EP2006/008171 external-priority patent/WO2007020103A2/en

2006-08-18 Priority claimed from US11/506,524 external-priority patent/US20070043120A1/en

2006-08-18 Priority claimed from US11/506,578 external-priority patent/US20070048372A1/en

2006-08-18 Priority claimed from US11/506,577 external-priority patent/US20070042969A1/en

2007-06-07 Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh

2008-04-01 Publication of TW200814988A publication Critical patent/TW200814988A/zh

Links

230000001225 therapeutic effect Effects 0.000 title claims abstract description 27
208000002193 Pain Diseases 0.000 claims abstract description 186
230000036407 pain Effects 0.000 claims abstract description 169
239000003795 chemical substances by application Substances 0.000 claims abstract description 155
150000001875 compounds Chemical class 0.000 claims abstract description 98
238000011282 treatment Methods 0.000 claims abstract description 52
150000003839 salts Chemical class 0.000 claims abstract description 49
230000002917 arthritic effect Effects 0.000 claims abstract description 36
239000002552 dosage form Substances 0.000 claims abstract description 28
VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims abstract description 7
229960002623 lacosamide Drugs 0.000 claims abstract description 6
-1 lower-grade Chemical group 0.000 claims description 104
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 103
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 82
125000000217 alkyl group Chemical group 0.000 claims description 79
125000003118 aryl group Chemical group 0.000 claims description 65
230000000694 effects Effects 0.000 claims description 57
239000001257 hydrogen Substances 0.000 claims description 55
229910052739 hydrogen Inorganic materials 0.000 claims description 55
201000008482 osteoarthritis Diseases 0.000 claims description 54
229960005181 morphine Drugs 0.000 claims description 48
125000000623 heterocyclic group Chemical group 0.000 claims description 45
230000002757 inflammatory effect Effects 0.000 claims description 44
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 41
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 38
206010065390 Inflammatory pain Diseases 0.000 claims description 37
229960002870 gabapentin Drugs 0.000 claims description 37
208000004296 neuralgia Diseases 0.000 claims description 36
208000004454 Hyperalgesia Diseases 0.000 claims description 31
206010003246 arthritis Diseases 0.000 claims description 31
208000021722 neuropathic pain Diseases 0.000 claims description 31
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 30
206010012601 diabetes mellitus Diseases 0.000 claims description 29
229960004640 memantine Drugs 0.000 claims description 29
125000006575 electron-withdrawing group Chemical group 0.000 claims description 28
125000000304 alkynyl group Chemical group 0.000 claims description 26
125000005843 halogen group Chemical group 0.000 claims description 25
125000003342 alkenyl group Chemical group 0.000 claims description 24
229960002866 duloxetine Drugs 0.000 claims description 23
239000003814 drug Substances 0.000 claims description 22
125000001424 substituent group Chemical group 0.000 claims description 21
208000024891 symptom Diseases 0.000 claims description 21
206010039073 rheumatoid arthritis Diseases 0.000 claims description 20
125000003545 alkoxy group Chemical group 0.000 claims description 19
150000001412 amines Chemical class 0.000 claims description 18
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
208000035154 Hyperesthesia Diseases 0.000 claims description 16
125000000753 cycloalkyl group Chemical group 0.000 claims description 15
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
210000000988 bone and bone Anatomy 0.000 claims description 13
206010034620 Peripheral sensory neuropathy Diseases 0.000 claims description 12
229960001233 pregabalin Drugs 0.000 claims description 12
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 12
201000005572 sensory peripheral neuropathy Diseases 0.000 claims description 12
208000000112 Myalgia Diseases 0.000 claims description 11
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 11
239000000730 antalgic agent Substances 0.000 claims description 11
229960002009 naproxen Drugs 0.000 claims description 11
125000004076 pyridyl group Chemical group 0.000 claims description 11
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 10
208000000094 Chronic Pain Diseases 0.000 claims description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
206010019233 Headaches Diseases 0.000 claims description 10
239000002253 acid Substances 0.000 claims description 10
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 10
229960004193 dextropropoxyphene Drugs 0.000 claims description 10
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 10
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 10
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 9
239000000935 antidepressant agent Substances 0.000 claims description 9
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 9
125000000714 pyrimidinyl group Chemical group 0.000 claims description 9
208000011580 syndromic disease Diseases 0.000 claims description 9
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 8
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 8
DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 claims description 8
229940005513 antidepressants Drugs 0.000 claims description 8
230000008355 cartilage degradation Effects 0.000 claims description 8
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
229960001797 methadone Drugs 0.000 claims description 8
125000002971 oxazolyl group Chemical group 0.000 claims description 8
208000008035 Back Pain Diseases 0.000 claims description 7
150000001335 aliphatic alkanes Chemical class 0.000 claims description 7
125000003282 alkyl amino group Chemical group 0.000 claims description 7
125000004414 alkyl thio group Chemical group 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 7
125000002541 furyl group Chemical group 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
150000003573 thiols Chemical class 0.000 claims description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
208000001640 Fibromyalgia Diseases 0.000 claims description 6
ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 claims description 6
208000019695 Migraine disease Diseases 0.000 claims description 6
239000008896 Opium Substances 0.000 claims description 6
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 6
229940035676 analgesics Drugs 0.000 claims description 6
239000001961 anticonvulsive agent Substances 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
229960003029 ketobemidone Drugs 0.000 claims description 6
206010027599 migraine Diseases 0.000 claims description 6
229960001027 opium Drugs 0.000 claims description 6
230000002093 peripheral effect Effects 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 claims description 6
230000000472 traumatic effect Effects 0.000 claims description 6
YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 claims description 5
208000006820 Arthralgia Diseases 0.000 claims description 5
OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims description 5
OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims description 5
206010065952 Hyperpathia Diseases 0.000 claims description 5
208000003456 Juvenile Arthritis Diseases 0.000 claims description 5
206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 5
229940127523 NMDA Receptor Antagonists Drugs 0.000 claims description 5
206010028980 Neoplasm Diseases 0.000 claims description 5
208000005890 Neuroma Diseases 0.000 claims description 5
208000010886 Peripheral nerve injury Diseases 0.000 claims description 5
AJOQSQHYDOFIOX-UHFFFAOYSA-N Pheneturide Chemical compound NC(=O)NC(=O)C(CC)C1=CC=CC=C1 AJOQSQHYDOFIOX-UHFFFAOYSA-N 0.000 claims description 5
208000001407 Vascular Headaches Diseases 0.000 claims description 5
230000001154 acute effect Effects 0.000 claims description 5
208000005298 acute pain Diseases 0.000 claims description 5
201000011510 cancer Diseases 0.000 claims description 5
230000008859 change Effects 0.000 claims description 5
238000002512 chemotherapy Methods 0.000 claims description 5
208000019069 chronic childhood arthritis Diseases 0.000 claims description 5
230000001684 chronic effect Effects 0.000 claims description 5
229960004126 codeine Drugs 0.000 claims description 5
229960004578 ethylmorphine Drugs 0.000 claims description 5
231100000869 headache Toxicity 0.000 claims description 5
125000002883 imidazolyl group Chemical group 0.000 claims description 5
201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 5
229960004002 levetiracetam Drugs 0.000 claims description 5
HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims description 5
125000002098 pyridazinyl group Chemical group 0.000 claims description 5
238000001959 radiotherapy Methods 0.000 claims description 5
229950000659 remacemide Drugs 0.000 claims description 5
238000007634 remodeling Methods 0.000 claims description 5
YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 claims description 4
UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 claims description 4
LGFMXOTUSSVQJV-NEYUFSEYSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;(4r,4ar,7s,7ar,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;1-[(3,4-dimethoxyphenyl)methyl]-6 Chemical compound Cl.Cl.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 LGFMXOTUSSVQJV-NEYUFSEYSA-N 0.000 claims description 4
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 4
YNZFUWZUGRBMHL-UHFFFAOYSA-N 2-[4-[3-(11-benzo[b][1]benzazepinyl)propyl]-1-piperazinyl]ethanol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 claims description 4
206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims description 4
206010009900 Colitis ulcerative Diseases 0.000 claims description 4
IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims description 4
201000005569 Gout Diseases 0.000 claims description 4
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 4
206010020751 Hypersensitivity Diseases 0.000 claims description 4
208000004575 Infectious Arthritis Diseases 0.000 claims description 4
208000012659 Joint disease Diseases 0.000 claims description 4
208000016604 Lyme disease Diseases 0.000 claims description 4
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 4
IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims description 4
UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 claims description 4
ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 claims description 4
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 4
UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 4
208000004983 Phantom Limb Diseases 0.000 claims description 4
206010056238 Phantom pain Diseases 0.000 claims description 4
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 4
201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
229960001391 alfentanil Drugs 0.000 claims description 4
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 4
208000026935 allergic disease Diseases 0.000 claims description 4
KGYFOSCXVAXULR-UHFFFAOYSA-N allylprodine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCN(C)CC1CC=C KGYFOSCXVAXULR-UHFFFAOYSA-N 0.000 claims description 4
229950004361 allylprodine Drugs 0.000 claims description 4
UVAZQQHAVMNMHE-XJKSGUPXSA-N alphaprodine Chemical compound C=1C=CC=CC=1[C@@]1(OC(=O)CC)CCN(C)C[C@@H]1C UVAZQQHAVMNMHE-XJKSGUPXSA-N 0.000 claims description 4
229960001349 alphaprodine Drugs 0.000 claims description 4
229960003805 amantadine Drugs 0.000 claims description 4
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 claims description 4
FLKWNFFCSSJANB-UHFFFAOYSA-N bezitramide Chemical compound O=C1N(C(=O)CC)C2=CC=CC=C2N1C(CC1)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 FLKWNFFCSSJANB-UHFFFAOYSA-N 0.000 claims description 4
229960004611 bezitramide Drugs 0.000 claims description 4
IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims description 4
229960001113 butorphanol Drugs 0.000 claims description 4
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 4
229960000623 carbamazepine Drugs 0.000 claims description 4
239000004075 cariostatic agent Substances 0.000 claims description 4
208000002849 chondrocalcinosis Diseases 0.000 claims description 4
GPZLDQAEBHTMPG-UHFFFAOYSA-N clonitazene Chemical compound N=1C2=CC([N+]([O-])=O)=CC=C2N(CCN(CC)CC)C=1CC1=CC=C(Cl)C=C1 GPZLDQAEBHTMPG-UHFFFAOYSA-N 0.000 claims description 4
229950001604 clonitazene Drugs 0.000 claims description 4
238000007906 compression Methods 0.000 claims description 4
230000006835 compression Effects 0.000 claims description 4
229950002213 cyclazocine Drugs 0.000 claims description 4
LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 claims description 4
229950003851 desomorphine Drugs 0.000 claims description 4
WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 claims description 4
INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 claims description 4
229960003701 dextromoramide Drugs 0.000 claims description 4
229960003461 dezocine Drugs 0.000 claims description 4
VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims description 4
125000004663 dialkyl amino group Chemical group 0.000 claims description 4
229960002069 diamorphine Drugs 0.000 claims description 4
RXTHKWVSXOIHJS-UHFFFAOYSA-N diampromide Chemical compound C=1C=CC=CC=1N(C(=O)CC)CC(C)N(C)CCC1=CC=CC=C1 RXTHKWVSXOIHJS-UHFFFAOYSA-N 0.000 claims description 4
229950001059 diampromide Drugs 0.000 claims description 4
229960000920 dihydrocodeine Drugs 0.000 claims description 4
RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims description 4
RHUWRJWFHUKVED-UHFFFAOYSA-N dimenoxadol Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(C)C)(OCC)C1=CC=CC=C1 RHUWRJWFHUKVED-UHFFFAOYSA-N 0.000 claims description 4
229950011187 dimenoxadol Drugs 0.000 claims description 4
LQGIXNQCOXNCRP-UHFFFAOYSA-N dioxaphetyl butyrate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)OCC)CCN1CCOCC1 LQGIXNQCOXNCRP-UHFFFAOYSA-N 0.000 claims description 4
229950008972 dioxaphetyl butyrate Drugs 0.000 claims description 4
SVDHSZFEQYXRDC-UHFFFAOYSA-N dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 claims description 4
229960002500 dipipanone Drugs 0.000 claims description 4
125000003700 epoxy group Chemical group 0.000 claims description 4
ZOWQTJXNFTWSCS-IAQYHMDHSA-N eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 claims description 4
229950010920 eptazocine Drugs 0.000 claims description 4
WGJHHMKQBWSQIY-UHFFFAOYSA-N ethoheptazine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCCN(C)CC1 WGJHHMKQBWSQIY-UHFFFAOYSA-N 0.000 claims description 4
229960000569 ethoheptazine Drugs 0.000 claims description 4
HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims description 4
PXDBZSCGSQSKST-UHFFFAOYSA-N etonitazene Chemical compound C1=CC(OCC)=CC=C1CC1=NC2=CC([N+]([O-])=O)=CC=C2N1CCN(CC)CC PXDBZSCGSQSKST-UHFFFAOYSA-N 0.000 claims description 4
229950004538 etonitazene Drugs 0.000 claims description 4
229960002428 fentanyl Drugs 0.000 claims description 4
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 4
125000001188 haloalkyl group Chemical group 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 4
229960000240 hydrocodone Drugs 0.000 claims description 4
WTJBNMUWRKPFRS-UHFFFAOYSA-N hydroxypethidine Chemical compound C=1C=CC(O)=CC=1C1(C(=O)OCC)CCN(C)CC1 WTJBNMUWRKPFRS-UHFFFAOYSA-N 0.000 claims description 4
229950008496 hydroxypethidine Drugs 0.000 claims description 4
230000009610 hypersensitivity Effects 0.000 claims description 4
IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 claims description 4
229950009272 isomethadone Drugs 0.000 claims description 4
229960001848 lamotrigine Drugs 0.000 claims description 4
PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 4
IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 claims description 4
229950010274 lofentanil Drugs 0.000 claims description 4
JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims description 4
229960000365 meptazinol Drugs 0.000 claims description 4
229950009131 metazocine Drugs 0.000 claims description 4
YGSVZRIZCHZUHB-COLVAYQJSA-N metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 claims description 4
NPZXCTIHHUUEEJ-CMKMFDCUSA-N metopon Chemical compound O([C@@]1(C)C(=O)CC[C@@H]23)C4=C5[C@@]13CCN(C)[C@@H]2CC5=CC=C4O NPZXCTIHHUUEEJ-CMKMFDCUSA-N 0.000 claims description 4
229950006080 metopon Drugs 0.000 claims description 4
125000002757 morpholinyl group Chemical group 0.000 claims description 4
229960000805 nalbuphine Drugs 0.000 claims description 4
NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims description 4
229960000938 nalorphine Drugs 0.000 claims description 4
230000001272 neurogenic effect Effects 0.000 claims description 4
201000001119 neuropathy Diseases 0.000 claims description 4
230000007823 neuropathy Effects 0.000 claims description 4
229960004300 nicomorphine Drugs 0.000 claims description 4
HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 claims description 4
229960004013 normethadone Drugs 0.000 claims description 4
WCJFBSYALHQBSK-UHFFFAOYSA-N normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 claims description 4
229950006134 normorphine Drugs 0.000 claims description 4
229950007418 norpipanone Drugs 0.000 claims description 4
WCDSHELZWCOTMI-UHFFFAOYSA-N norpipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CCN1CCCCC1 WCDSHELZWCOTMI-UHFFFAOYSA-N 0.000 claims description 4
229960005290 opipramol Drugs 0.000 claims description 4
229960001816 oxcarbazepine Drugs 0.000 claims description 4
CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims description 4
229960002085 oxycodone Drugs 0.000 claims description 4
229960005118 oxymorphone Drugs 0.000 claims description 4
229960003294 papaveretum Drugs 0.000 claims description 4
229960005489 paracetamol Drugs 0.000 claims description 4
238000007911 parenteral administration Methods 0.000 claims description 4
VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims description 4
229960005301 pentazocine Drugs 0.000 claims description 4
208000033808 peripheral neuropathy Diseases 0.000 claims description 4
229960000482 pethidine Drugs 0.000 claims description 4
LOXCOAXRHYDLOW-UHFFFAOYSA-N phenadoxone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCOCC1 LOXCOAXRHYDLOW-UHFFFAOYSA-N 0.000 claims description 4
229950004540 phenadoxone Drugs 0.000 claims description 4
ZQHYKVKNPWDQSL-KNXBSLHKSA-N phenazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-KNXBSLHKSA-N 0.000 claims description 4
229960000897 phenazocine Drugs 0.000 claims description 4
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims description 4
229950010883 phencyclidine Drugs 0.000 claims description 4
CFBQYWXPZVQQTN-QPTUXGOLSA-N phenomorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CCC1=CC=CC=C1 CFBQYWXPZVQQTN-QPTUXGOLSA-N 0.000 claims description 4
229950011496 phenomorphan Drugs 0.000 claims description 4
IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 claims description 4
229960004315 phenoperidine Drugs 0.000 claims description 4
229960002036 phenytoin Drugs 0.000 claims description 4
PXXKIYPSXYFATG-UHFFFAOYSA-N piminodine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCCNC1=CC=CC=C1 PXXKIYPSXYFATG-UHFFFAOYSA-N 0.000 claims description 4
229950006445 piminodine Drugs 0.000 claims description 4
IHEHEFLXQFOQJO-UHFFFAOYSA-N piritramide Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 IHEHEFLXQFOQJO-UHFFFAOYSA-N 0.000 claims description 4
229960001286 piritramide Drugs 0.000 claims description 4
ZXWAUWBYASJEOE-UHFFFAOYSA-N proheptazine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCCN(C)CC1C ZXWAUWBYASJEOE-UHFFFAOYSA-N 0.000 claims description 4
229950010387 proheptazine Drugs 0.000 claims description 4
229950004345 properidine Drugs 0.000 claims description 4
XJKQCILVUHXVIQ-UHFFFAOYSA-N properidine Chemical compound C=1C=CC=CC=1C1(C(=O)OC(C)C)CCN(C)CC1 XJKQCILVUHXVIQ-UHFFFAOYSA-N 0.000 claims description 4
229950003779 propiram Drugs 0.000 claims description 4
ZBAFFZBKCMWUHM-UHFFFAOYSA-N propiram Chemical compound C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 ZBAFFZBKCMWUHM-UHFFFAOYSA-N 0.000 claims description 4
125000000168 pyrrolyl group Chemical group 0.000 claims description 4
125000001453 quaternary ammonium group Chemical group 0.000 claims description 4
201000000306 sarcoidosis Diseases 0.000 claims description 4
201000001223 septic arthritis Diseases 0.000 claims description 4
230000002269 spontaneous effect Effects 0.000 claims description 4
GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims description 4
229960004739 sufentanil Drugs 0.000 claims description 4
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
125000000335 thiazolyl group Chemical group 0.000 claims description 4
QAXBVGVYDCAVLV-UHFFFAOYSA-N tiletamine Chemical compound C=1C=CSC=1C1(NCC)CCCCC1=O QAXBVGVYDCAVLV-UHFFFAOYSA-N 0.000 claims description 4
229960001402 tilidine Drugs 0.000 claims description 4
229960004380 tramadol Drugs 0.000 claims description 4
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 4
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 4
206010044652 trigeminal neuralgia Diseases 0.000 claims description 4
ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 4
229960002431 trimipramine Drugs 0.000 claims description 4
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 3
UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 claims description 3
GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 3
IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 3
YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims description 3
VOROEQBFPPIACJ-SCSAIBSYSA-N (2r)-2-amino-5-phosphonopentanoic acid Chemical compound OC(=O)[C@H](N)CCCP(O)(O)=O VOROEQBFPPIACJ-SCSAIBSYSA-N 0.000 claims description 3
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 3
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 3
BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 3
NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 claims description 3
IYNWSQDZXMGGGI-NUEKZKHPSA-N 3-hydroxymorphinan Chemical compound C1CCC[C@H]2[C@H]3CC4=CC=C(O)C=C4[C@]21CCN3 IYNWSQDZXMGGGI-NUEKZKHPSA-N 0.000 claims description 3
JYJFNDQBESEHJQ-UHFFFAOYSA-N 5,5-dimethyloxazolidine-2,4-dione Chemical compound CC1(C)OC(=O)NC1=O JYJFNDQBESEHJQ-UHFFFAOYSA-N 0.000 claims description 3
FEJIIZAOQRTGPC-UHFFFAOYSA-N 5,5-diphenylimidazolidin-4-one Chemical compound O=C1NCNC1(C=1C=CC=CC=1)C1=CC=CC=C1 FEJIIZAOQRTGPC-UHFFFAOYSA-N 0.000 claims description 3
BGKFPRIGXAVYNX-UHFFFAOYSA-N 5,7-dichloro-4-oxo-1H-quinoline-2-carboxylic acid Chemical compound ClC1=CC(Cl)=CC2=NC(C(=O)O)=CC(O)=C21 BGKFPRIGXAVYNX-UHFFFAOYSA-N 0.000 claims description 3
MXUNKHLAEDCYJL-UHFFFAOYSA-N 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 claims description 3
QPGGEKPRGVJKQB-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl]-11-methyl-6-benzo[b][1,4]benzodiazepinone Chemical compound O=C1N(CCN(C)C)C2=CC=CC=C2N(C)C2=CC=CC=C21 QPGGEKPRGVJKQB-UHFFFAOYSA-N 0.000 claims description 3
NEGMMKYAVYNLCG-UHFFFAOYSA-N 5-ethyl-1-methyl-5-phenylimidazolidine-2,4-dione Chemical compound C=1C=CC=CC=1C1(CC)N(C)C(=O)NC1=O NEGMMKYAVYNLCG-UHFFFAOYSA-N 0.000 claims description 3
XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 claims description 3
JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 claims description 3
206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
208000027496 Behcet disease Diseases 0.000 claims description 3
208000009137 Behcet syndrome Diseases 0.000 claims description 3
DKHJWWRYTONYHB-UHFFFAOYSA-N CPP Chemical compound OC(=O)C(C)OC1=CC=C(Cl)C=C1 DKHJWWRYTONYHB-UHFFFAOYSA-N 0.000 claims description 3
PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 claims description 3
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 3
UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 claims description 3
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 3
SIGSNYAYBSJATD-UHFFFAOYSA-N Ethadione Chemical compound CCN1C(=O)OC(C)(C)C1=O SIGSNYAYBSJATD-UHFFFAOYSA-N 0.000 claims description 3
XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 claims description 3
PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 claims description 3
MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 claims description 3
NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 claims description 3
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 3
AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 claims description 3
UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims description 3
WGMASVSHOSNKMF-UHFFFAOYSA-N Narcobarbital Chemical compound BrC(=C)CC1(C(C)C)C(=O)NC(=O)N(C)C1=O WGMASVSHOSNKMF-UHFFFAOYSA-N 0.000 claims description 3
RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 claims description 3
206010029174 Nerve compression Diseases 0.000 claims description 3
208000028389 Nerve injury Diseases 0.000 claims description 3
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 3
XCWPUUGSGHNIDZ-UHFFFAOYSA-N Oxypertine Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C)=C1CCN(CC1)CCN1C1=CC=CC=C1 XCWPUUGSGHNIDZ-UHFFFAOYSA-N 0.000 claims description 3
VQASKUSHBVDKGU-UHFFFAOYSA-N Paramethadione Chemical compound CCC1(C)OC(=O)N(C)C1=O VQASKUSHBVDKGU-UHFFFAOYSA-N 0.000 claims description 3
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 3
RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 claims description 3
WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 claims description 3
206010037660 Pyrexia Diseases 0.000 claims description 3
208000033464 Reiter syndrome Diseases 0.000 claims description 3
HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 claims description 3
JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 claims description 3
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 3
208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
229960002820 adrafinil Drugs 0.000 claims description 3
CGNMLOKEMNBUAI-UHFFFAOYSA-N adrafinil Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)NO)C1=CC=CC=C1 CGNMLOKEMNBUAI-UHFFFAOYSA-N 0.000 claims description 3
206010053552 allodynia Diseases 0.000 claims description 3
229960000959 amineptine Drugs 0.000 claims description 3
VDPUXONTAVMIKZ-UHFFFAOYSA-N amineptine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2C([NH2+]CCCCCCC(=O)O)C2=CC=CC=C21 VDPUXONTAVMIKZ-UHFFFAOYSA-N 0.000 claims description 3
229960000836 amitriptyline Drugs 0.000 claims description 3
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 3
229960002980 amitriptyline oxide Drugs 0.000 claims description 3
ZPMKQFOGINQDAM-UHFFFAOYSA-N amitriptylinoxide Chemical compound C1CC2=CC=CC=C2C(=CCC[N+](C)([O-])C)C2=CC=CC=C21 ZPMKQFOGINQDAM-UHFFFAOYSA-N 0.000 claims description 3
229960002519 amoxapine Drugs 0.000 claims description 3
QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims description 3
BFNCJMURTMZBTE-UHFFFAOYSA-N aptiganel Chemical compound CCC1=CC=CC(N(C)C(N)=NC=2C3=CC=CC=C3C=CC=2)=C1 BFNCJMURTMZBTE-UHFFFAOYSA-N 0.000 claims description 3
229950001180 aptiganel Drugs 0.000 claims description 3
125000002393 azetidinyl group Chemical group 0.000 claims description 3
125000004069 aziridinyl group Chemical group 0.000 claims description 3
229960005200 beclamide Drugs 0.000 claims description 3
JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 claims description 3
229950000017 befloxatone Drugs 0.000 claims description 3
IALVDLPLCLFBCF-CHWSQXEVSA-N befloxatone Chemical compound O=C1O[C@@H](COC)CN1C1=CC=C(OCC[C@@H](O)C(F)(F)F)C=C1 IALVDLPLCLFBCF-CHWSQXEVSA-N 0.000 claims description 3
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 3
229960001736 buprenorphine Drugs 0.000 claims description 3
229960001058 bupropion Drugs 0.000 claims description 3
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 3
YFLRYAVDPKONNX-UHFFFAOYSA-N buramate Chemical compound OCCOC(=O)NCC1=CC=CC=C1 YFLRYAVDPKONNX-UHFFFAOYSA-N 0.000 claims description 3
229950009824 buramate Drugs 0.000 claims description 3
229960004301 butriptyline Drugs 0.000 claims description 3
ALELTFCQZDXAMQ-UHFFFAOYSA-N butriptyline Chemical compound C1CC2=CC=CC=C2C(CC(C)CN(C)C)C2=CC=CC=C21 ALELTFCQZDXAMQ-UHFFFAOYSA-N 0.000 claims description 3
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 3
KYCBWEZLKCTALM-UHFFFAOYSA-N caroxazone Chemical compound C1=CC=C2OC(=O)N(CC(=O)N)CC2=C1 KYCBWEZLKCTALM-UHFFFAOYSA-N 0.000 claims description 3
229950006044 caroxazone Drugs 0.000 claims description 3
LDCXGZCEMNMWIL-VOTSOKGWSA-N cinromide Chemical compound CCNC(=O)\C=C\C1=CC=CC(Br)=C1 LDCXGZCEMNMWIL-VOTSOKGWSA-N 0.000 claims description 3
229950008460 cinromide Drugs 0.000 claims description 3
229960004414 clomethiazole Drugs 0.000 claims description 3
229960004606 clomipramine Drugs 0.000 claims description 3
229960003120 clonazepam Drugs 0.000 claims description 3
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 3
229950006073 cotinine Drugs 0.000 claims description 3
REYUZOLYIOQRIG-UHFFFAOYSA-N decimemide Chemical compound CCCCCCCCCCOC1=C(OC)C=C(C(N)=O)C=C1OC REYUZOLYIOQRIG-UHFFFAOYSA-N 0.000 claims description 3
229950011023 decimemide Drugs 0.000 claims description 3
229950010189 demexiptiline Drugs 0.000 claims description 3
SEDQWOMFMIJKCU-UHFFFAOYSA-N demexiptiline Chemical compound C1=CC2=CC=CC=C2C(=NOCCNC)C2=CC=CC=C21 SEDQWOMFMIJKCU-UHFFFAOYSA-N 0.000 claims description 3
229960003914 desipramine Drugs 0.000 claims description 3
SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 claims description 3
HGKAMARNFGKMLC-RBUKOAKNSA-N dexoxadrol Chemical compound C([C@H]1[C@@H]2OC(OC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCN1 HGKAMARNFGKMLC-RBUKOAKNSA-N 0.000 claims description 3
229960001985 dextromethorphan Drugs 0.000 claims description 3
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 3
229960003075 dibenzepin Drugs 0.000 claims description 3
ORTYMGHCFWKXHO-UHFFFAOYSA-N diethadione Chemical compound CCC1(CC)COC(=O)NC1=O ORTYMGHCFWKXHO-UHFFFAOYSA-N 0.000 claims description 3
229960003675 diethadione Drugs 0.000 claims description 3
QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 claims description 3
229950004655 dimepheptanol Drugs 0.000 claims description 3
229960003524 dimetacrine Drugs 0.000 claims description 3
RYQOGSFEJBUZBX-UHFFFAOYSA-N dimetacrine Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1 RYQOGSFEJBUZBX-UHFFFAOYSA-N 0.000 claims description 3
229950004446 dimethadione Drugs 0.000 claims description 3
CMKUGKVVUUGBHJ-UHFFFAOYSA-N dimethazan Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCN(C)C CMKUGKVVUUGBHJ-UHFFFAOYSA-N 0.000 claims description 3
229950002134 dimethazan Drugs 0.000 claims description 3
229950006161 dioxadrol Drugs 0.000 claims description 3
125000002228 disulfide group Chemical group 0.000 claims description 3
QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 claims description 3
229960001393 dosulepin Drugs 0.000 claims description 3
229950004453 doxenitoin Drugs 0.000 claims description 3
229960005426 doxepin Drugs 0.000 claims description 3
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 3
229960000262 ethadione Drugs 0.000 claims description 3
229960002767 ethosuximide Drugs 0.000 claims description 3
SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 claims description 3
229960003533 ethotoin Drugs 0.000 claims description 3
IZBNNCFOBMGTQX-UHFFFAOYSA-N etoperidone Chemical compound O=C1N(CC)C(CC)=NN1CCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 IZBNNCFOBMGTQX-UHFFFAOYSA-N 0.000 claims description 3
229960005437 etoperidone Drugs 0.000 claims description 3
229960003472 felbamate Drugs 0.000 claims description 3
WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims description 3
229950003930 femoxetine Drugs 0.000 claims description 3
OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 claims description 3
PDTADBTVZXKSJM-UHFFFAOYSA-N fencamine Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(C)C=1NCCN(C)C(C)CC1=CC=CC=C1 PDTADBTVZXKSJM-UHFFFAOYSA-N 0.000 claims description 3
SNJDSTGQYRTZJT-UHFFFAOYSA-N fenpentadiol Chemical compound CC(C)(O)CC(C)(O)C1=CC=C(Cl)C=C1 SNJDSTGQYRTZJT-UHFFFAOYSA-N 0.000 claims description 3
229950011196 fenpentadiol Drugs 0.000 claims description 3
229950002413 fluacizine Drugs 0.000 claims description 3
VHEOUJNDDFHPGJ-UHFFFAOYSA-N fluacizine Chemical compound C1=C(C(F)(F)F)C=C2N(C(=O)CCN(CC)CC)C3=CC=CC=C3SC2=C1 VHEOUJNDDFHPGJ-UHFFFAOYSA-N 0.000 claims description 3
PRNNIHPVNFPWAH-UHFFFAOYSA-N fluoresone Chemical compound CCS(=O)(=O)C1=CC=C(F)C=C1 PRNNIHPVNFPWAH-UHFFFAOYSA-N 0.000 claims description 3
229950011300 fluoresone Drugs 0.000 claims description 3
229960002464 fluoxetine Drugs 0.000 claims description 3
229960004038 fluvoxamine Drugs 0.000 claims description 3
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 3
229960000693 fosphenytoin Drugs 0.000 claims description 3
229950006567 ganaxolone Drugs 0.000 claims description 3
229940005608 hypericin Drugs 0.000 claims description 3
PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 claims description 3
125000002632 imidazolidinyl group Chemical group 0.000 claims description 3
125000002636 imidazolinyl group Chemical group 0.000 claims description 3
229960004801 imipramine Drugs 0.000 claims description 3
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 3
229960003441 imipramine oxide Drugs 0.000 claims description 3
QZIQORUGXBPDSU-UHFFFAOYSA-N imipramine oxide Chemical compound C1CC2=CC=CC=C2N(CCC[N+](C)([O-])C)C2=CC=CC=C21 QZIQORUGXBPDSU-UHFFFAOYSA-N 0.000 claims description 3
229960004333 indeloxazine Drugs 0.000 claims description 3
229940070023 iproniazide Drugs 0.000 claims description 3
229960002672 isocarboxazid Drugs 0.000 claims description 3
229960003299 ketamine Drugs 0.000 claims description 3
RCYBMSQOSGJZLO-BGWNEDDSSA-N levophenacylmorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CC(=O)C1=CC=CC=C1 RCYBMSQOSGJZLO-BGWNEDDSSA-N 0.000 claims description 3
229950007939 levophenacylmorphan Drugs 0.000 claims description 3
CHFSOFHQIZKQCR-UHFFFAOYSA-N licostinel Chemical compound N1C(=O)C(=O)NC2=C1C=C(Cl)C(Cl)=C2[N+](=O)[O-] CHFSOFHQIZKQCR-UHFFFAOYSA-N 0.000 claims description 3
229950010467 licostinel Drugs 0.000 claims description 3
229960004391 lorazepam Drugs 0.000 claims description 3
239000012528 membrane Substances 0.000 claims description 3
ALARQZQTBTVLJV-UHFFFAOYSA-N mephobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 claims description 3
229960003729 mesuximide Drugs 0.000 claims description 3
229950007330 metetoin Drugs 0.000 claims description 3
229960001703 methylphenobarbital Drugs 0.000 claims description 3
229960003955 mianserin Drugs 0.000 claims description 3
229960003793 midazolam Drugs 0.000 claims description 3
DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims description 3
229960000600 milnacipran Drugs 0.000 claims description 3
229960004758 minaprine Drugs 0.000 claims description 3
LDMWSLGGVTVJPG-UHFFFAOYSA-N minaprine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 LDMWSLGGVTVJPG-UHFFFAOYSA-N 0.000 claims description 3
229960001785 mirtazapine Drugs 0.000 claims description 3
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims description 3
229960004644 moclobemide Drugs 0.000 claims description 3
YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 3
AKFJWRDCWYYTIG-ZDUSSCGKSA-N naproxcinod Chemical compound C1=C([C@H](C)C(=O)OCCCCO[N+]([O-])=O)C=CC2=CC(OC)=CC=C21 AKFJWRDCWYYTIG-ZDUSSCGKSA-N 0.000 claims description 3
229960002323 narcobarbital Drugs 0.000 claims description 3
229960001800 nefazodone Drugs 0.000 claims description 3
VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims description 3
229960000751 nefopam Drugs 0.000 claims description 3
230000008764 nerve damage Effects 0.000 claims description 3
230000000926 neurological effect Effects 0.000 claims description 3
229960003057 nialamide Drugs 0.000 claims description 3
KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 claims description 3
229960001454 nitrazepam Drugs 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
229960001073 nomifensine Drugs 0.000 claims description 3
XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 claims description 3
229950011519 norlevorphanol Drugs 0.000 claims description 3
229960001158 nortriptyline Drugs 0.000 claims description 3
GPTURHKXTUDRPC-UHFFFAOYSA-N noxiptiline Chemical compound C1CC2=CC=CC=C2C(=NOCCN(C)C)C2=CC=CC=C21 GPTURHKXTUDRPC-UHFFFAOYSA-N 0.000 claims description 3
229950004461 noxiptiline Drugs 0.000 claims description 3
FODQIVGFADUBKE-UHFFFAOYSA-N octamoxin Chemical compound CCCCCCC(C)NN FODQIVGFADUBKE-UHFFFAOYSA-N 0.000 claims description 3
229950006863 octamoxin Drugs 0.000 claims description 3
125000003566 oxetanyl group Chemical group 0.000 claims description 3
229960002841 oxypertine Drugs 0.000 claims description 3
229960003274 paramethadione Drugs 0.000 claims description 3
229960002296 paroxetine Drugs 0.000 claims description 3
230000008447 perception Effects 0.000 claims description 3
229960000964 phenelzine Drugs 0.000 claims description 3
229960003877 pheneturide Drugs 0.000 claims description 3
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 3
229960002695 phenobarbital Drugs 0.000 claims description 3
229960004227 phensuximide Drugs 0.000 claims description 3
ILORKHQGIMGDFN-UHFFFAOYSA-N phetharbital Chemical compound O=C1C(CC)(CC)C(=O)NC(=O)N1C1=CC=CC=C1 ILORKHQGIMGDFN-UHFFFAOYSA-N 0.000 claims description 3
229950000832 phetharbital Drugs 0.000 claims description 3
229950009306 piberaline Drugs 0.000 claims description 3
TZFUBYYADABEAV-UHFFFAOYSA-N piberaline Chemical compound C=1C=CC=NC=1C(=O)N(CC1)CCN1CC1=CC=CC=C1 TZFUBYYADABEAV-UHFFFAOYSA-N 0.000 claims description 3
229960004572 pizotifen Drugs 0.000 claims description 3
FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 claims description 3
DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims description 3
229960002393 primidone Drugs 0.000 claims description 3
229960002752 progabide Drugs 0.000 claims description 3
IBALRBWGSVJPAP-HEHNFIMWSA-N progabide Chemical compound C=1C(F)=CC=C(O)C=1C(=N/CCCC(=O)N)/C1=CC=C(Cl)C=C1 IBALRBWGSVJPAP-HEHNFIMWSA-N 0.000 claims description 3
229950003857 propizepine Drugs 0.000 claims description 3
YFLBETLXDPBWTD-UHFFFAOYSA-N propizepine Chemical compound O=C1N(CC(C)N(C)C)C2=CC=CC=C2NC2=NC=CC=C21 YFLBETLXDPBWTD-UHFFFAOYSA-N 0.000 claims description 3
229960002601 protriptyline Drugs 0.000 claims description 3
BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims description 3
SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 claims description 3
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 3
125000003226 pyrazolyl group Chemical group 0.000 claims description 3
229960000279 quinupramine Drugs 0.000 claims description 3
JCBQCKFFSPGEDY-UHFFFAOYSA-N quinupramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1C(C1)C2CCN1CC2 JCBQCKFFSPGEDY-UHFFFAOYSA-N 0.000 claims description 3
208000002574 reactive arthritis Diseases 0.000 claims description 3
229960003770 reboxetine Drugs 0.000 claims description 3
CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims description 3
JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 claims description 3
229950009626 ritanserin Drugs 0.000 claims description 3
229950000366 roxindole Drugs 0.000 claims description 3
BKTTWZADZNUOBW-UHFFFAOYSA-N roxindole Chemical compound C=12[CH]C(O)=CC=C2N=CC=1CCCCN(CC=1)CCC=1C1=CC=CC=C1 BKTTWZADZNUOBW-UHFFFAOYSA-N 0.000 claims description 3
229940102127 rubidium chloride Drugs 0.000 claims description 3
POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 claims description 3
229960003014 rufinamide Drugs 0.000 claims description 3
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 3
229960002073 sertraline Drugs 0.000 claims description 3
230000001568 sexual effect Effects 0.000 claims description 3
208000020431 spinal cord injury Diseases 0.000 claims description 3
ZWYUGDUPLSGYSK-UHFFFAOYSA-N spiro[2,4-dihydro-1h-naphthalene-3,5'-imidazolidine]-2',4'-dione Chemical compound N1C(=O)NC(=O)C11CC2=CC=CC=C2CC1 ZWYUGDUPLSGYSK-UHFFFAOYSA-N 0.000 claims description 3
JUIHCCIFJCSFON-UHFFFAOYSA-N suclofenide Chemical compound ClC1=CC(S(=O)(=O)N)=CC=C1N1C(=O)C(C=2C=CC=CC=2)CC1=O JUIHCCIFJCSFON-UHFFFAOYSA-N 0.000 claims description 3
229950011251 suclofenide Drugs 0.000 claims description 3
229960004940 sulpiride Drugs 0.000 claims description 3
229960002573 sultiame Drugs 0.000 claims description 3
229950004608 talampanel Drugs 0.000 claims description 3
229950000505 tandospirone Drugs 0.000 claims description 3
CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 claims description 3
125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 3
125000003831 tetrazolyl group Chemical group 0.000 claims description 3
JJSHYECKYLDYAR-UHFFFAOYSA-N thozalinone Chemical compound O1C(N(C)C)=NC(=O)C1C1=CC=CC=C1 JJSHYECKYLDYAR-UHFFFAOYSA-N 0.000 claims description 3
229960001918 tiagabine Drugs 0.000 claims description 3
PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims description 3
229960005138 tianeptine Drugs 0.000 claims description 3
QJJXOEFWXSQISU-UHFFFAOYSA-N tiazesim Chemical compound C1C(=O)N(CCN(C)C)C2=CC=CC=C2SC1C1=CC=CC=C1 QJJXOEFWXSQISU-UHFFFAOYSA-N 0.000 claims description 3
229950004626 tiazesim Drugs 0.000 claims description 3
PNYKGCPSFKLFKA-UHFFFAOYSA-N tofenacin Chemical compound C=1C=CC=C(C)C=1C(OCCNC)C1=CC=CC=C1 PNYKGCPSFKLFKA-UHFFFAOYSA-N 0.000 claims description 3
229950010076 tofenacin Drugs 0.000 claims description 3
229960002309 toloxatone Drugs 0.000 claims description 3
229960004394 topiramate Drugs 0.000 claims description 3
PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 claims description 3
229960003741 tranylcypromine Drugs 0.000 claims description 3
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 3
229960003991 trazodone Drugs 0.000 claims description 3
125000001425 triazolyl group Chemical group 0.000 claims description 3
229960004799 tryptophan Drugs 0.000 claims description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 3
229960000604 valproic acid Drugs 0.000 claims description 3
229960001930 valpromide Drugs 0.000 claims description 3
OMOMUFTZPTXCHP-UHFFFAOYSA-N valpromide Chemical compound CCCC(C(N)=O)CCC OMOMUFTZPTXCHP-UHFFFAOYSA-N 0.000 claims description 3
229960004688 venlafaxine Drugs 0.000 claims description 3
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 3
229960005318 vigabatrin Drugs 0.000 claims description 3
PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims description 3
229960001255 viloxazine Drugs 0.000 claims description 3
229960002911 zonisamide Drugs 0.000 claims description 3
UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims description 3
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims description 2
241001372585 Atatina Species 0.000 claims description 2
UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 claims description 2
XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 claims description 2
206010039491 Sarcoma Diseases 0.000 claims description 2
229950009984 acetylpheneturide Drugs 0.000 claims description 2
125000005262 alkoxyamine group Chemical group 0.000 claims description 2
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 2
229960003437 aminoglutethimide Drugs 0.000 claims description 2
229940125681 anticonvulsant agent Drugs 0.000 claims description 2
229960001716 benzalkonium Drugs 0.000 claims description 2
CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 claims description 2
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
DACOQFZGGLCXMA-UHFFFAOYSA-N eterobarb Chemical compound C=1C=CC=CC=1C1(CC)C(=O)N(COC)C(=O)N(COC)C1=O DACOQFZGGLCXMA-UHFFFAOYSA-N 0.000 claims description 2
229950009327 eterobarb Drugs 0.000 claims description 2
229950005000 gavestinel Drugs 0.000 claims description 2
229960003569 hematoporphyrin Drugs 0.000 claims description 2
229950010282 heptobarbital Drugs 0.000 claims description 2
LSAOZCAKUIANSQ-UHFFFAOYSA-N heptobarbital Chemical compound C=1C=CC=CC=1C1(C)C(=O)NC(=O)NC1=O LSAOZCAKUIANSQ-UHFFFAOYSA-N 0.000 claims description 2
229950002473 indalpine Drugs 0.000 claims description 2
SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 claims description 2
229960002589 iproclozide Drugs 0.000 claims description 2
GGECDTUJZOXAAR-UHFFFAOYSA-N iproclozide Chemical compound CC(C)NNC(=O)COC1=CC=C(Cl)C=C1 GGECDTUJZOXAAR-UHFFFAOYSA-N 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
125000001786 isothiazolyl group Chemical group 0.000 claims description 2
125000000842 isoxazolyl group Chemical group 0.000 claims description 2
230000000366 juvenile effect Effects 0.000 claims description 2
229950004771 levofacetoperane Drugs 0.000 claims description 2
BKPLVPRTTWIDNL-ZIAGYGMSSA-N levofacetoperane Chemical compound C([C@@H]1[C@H](OC(=O)C)C=2C=CC=CC=2)CCCN1 BKPLVPRTTWIDNL-ZIAGYGMSSA-N 0.000 claims description 2
229960002813 lofepramine Drugs 0.000 claims description 2
SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 claims description 2
STIRHCNEGQQBOY-QEYWKRMJSA-N ly-235,959 Chemical compound C1[C@@H](CP(O)(O)=O)CC[C@H]2CN[C@H](C(=O)O)C[C@H]21 STIRHCNEGQQBOY-QEYWKRMJSA-N 0.000 claims description 2
229960004794 melitracen Drugs 0.000 claims description 2
GWWLWDURRGNSRS-UHFFFAOYSA-N melitracen Chemical compound C1=CC=C2C(=CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1 GWWLWDURRGNSRS-UHFFFAOYSA-N 0.000 claims description 2
YXVZOBVWVRFPTE-UHFFFAOYSA-N metapramine Chemical compound CNC1CC2=CC=CC=C2N(C)C2=CC=CC=C12 YXVZOBVWVRFPTE-UHFFFAOYSA-N 0.000 claims description 2
229950006180 metapramine Drugs 0.000 claims description 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
230000000116 mitigating effect Effects 0.000 claims description 2
229960002019 oxaflozane Drugs 0.000 claims description 2
FVYUQFQCEOZYHZ-UHFFFAOYSA-N oxaflozane Chemical compound C1N(C(C)C)CCOC1C1=CC=CC(C(F)(F)F)=C1 FVYUQFQCEOZYHZ-UHFFFAOYSA-N 0.000 claims description 2
229960002888 oxitriptan Drugs 0.000 claims description 2
LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims description 2
229960003396 phenacemide Drugs 0.000 claims description 2
125000004193 piperazinyl group Chemical group 0.000 claims description 2
125000003386 piperidinyl group Chemical group 0.000 claims description 2
229960003295 pirisudanol Drugs 0.000 claims description 2
KTOAWCPDBUCJED-UHFFFAOYSA-N pirisudanol Chemical compound CN(C)CCOC(=O)CCC(=O)OCC1=CN=C(C)C(O)=C1CO KTOAWCPDBUCJED-UHFFFAOYSA-N 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
125000003072 pyrazolidinyl group Chemical group 0.000 claims description 2
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
125000001422 pyrrolinyl group Chemical group 0.000 claims description 2
125000005493 quinolyl group Chemical group 0.000 claims description 2
GRSDSTMFQHAESM-UHDJGPCESA-M sodium;3-[(e)-3-anilino-3-oxoprop-1-enyl]-4,6-dichloro-1h-indole-2-carboxylate Chemical compound [Na+].[O-]C(=O)C=1NC2=CC(Cl)=CC(Cl)=C2C=1\C=C\C(=O)NC1=CC=CC=C1 GRSDSTMFQHAESM-UHDJGPCESA-M 0.000 claims description 2
229960004523 tiletamine Drugs 0.000 claims description 2
231100000419 toxicity Toxicity 0.000 claims description 2
230000001988 toxicity Effects 0.000 claims description 2
150000002431 hydrogen Chemical group 0.000 claims 8
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 claims 3
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 claims 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 1
XDLJIIILKATPAQ-UHFFFAOYSA-N 2,8-dichloro-7h-purine Chemical compound ClC1=NC=C2NC(Cl)=NC2=N1 XDLJIIILKATPAQ-UHFFFAOYSA-N 0.000 claims 1
SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
206010058841 Adnexa uteri pain Diseases 0.000 claims 1
208000002177 Cataract Diseases 0.000 claims 1
206010062717 Increased upper airway secretion Diseases 0.000 claims 1
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
208000007101 Muscle Cramp Diseases 0.000 claims 1
150000001204 N-oxides Chemical class 0.000 claims 1
241001643667 Orpha Species 0.000 claims 1
229920002675 Polyoxyl Polymers 0.000 claims 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
208000005392 Spasm Diseases 0.000 claims 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
GJSLOMWRLALDCT-UHFFFAOYSA-N adinazolam Chemical compound C12=CC(Cl)=CC=C2N2C(CN(C)C)=NN=C2CN=C1C1=CC=CC=C1 GJSLOMWRLALDCT-UHFFFAOYSA-N 0.000 claims 1
229960003148 adinazolam Drugs 0.000 claims 1
150000001299 aldehydes Chemical class 0.000 claims 1
150000003973 alkyl amines Chemical class 0.000 claims 1
229940076134 benzene Drugs 0.000 claims 1
IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 claims 1
150000003857 carboxamides Chemical class 0.000 claims 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 claims 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
229960003350 isoniazid Drugs 0.000 claims 1
125000005956 isoquinolyl group Chemical group 0.000 claims 1
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 1
208000026435 phlegm Diseases 0.000 claims 1
230000002485 urinary effect Effects 0.000 claims 1
230000009467 reduction Effects 0.000 description 45
210000002414 leg Anatomy 0.000 description 40
238000000034 method Methods 0.000 description 36
238000012360 testing method Methods 0.000 description 29
241000700159 Rattus Species 0.000 description 26
125000004432 carbon atom Chemical group C* 0.000 description 26
238000002347 injection Methods 0.000 description 26
239000007924 injection Substances 0.000 description 26
230000002829 reductive effect Effects 0.000 description 24
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 23
102100040247 Tumor necrosis factor Human genes 0.000 description 23
229940079593 drug Drugs 0.000 description 21
241001465754 Metazoa Species 0.000 description 20
239000007928 intraperitoneal injection Substances 0.000 description 20
206010036790 Productive cough Diseases 0.000 description 19
239000000203 mixture Substances 0.000 description 19
210000003802 sputum Anatomy 0.000 description 19
208000024794 sputum Diseases 0.000 description 19
238000010255 intramuscular injection Methods 0.000 description 17
239000007927 intramuscular injection Substances 0.000 description 17
206010061218 Inflammation Diseases 0.000 description 16
230000004054 inflammatory process Effects 0.000 description 16
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 15
210000003205 muscle Anatomy 0.000 description 15
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
UNZIDPIPYUMVPA-UHFFFAOYSA-M Sulpyrine Chemical compound O.[Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 UNZIDPIPYUMVPA-UHFFFAOYSA-M 0.000 description 14
238000002474 experimental method Methods 0.000 description 14
230000002159 abnormal effect Effects 0.000 description 12
229960001259 diclofenac Drugs 0.000 description 11
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 11
229940120889 dipyrone Drugs 0.000 description 11
210000001503 joint Anatomy 0.000 description 11
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 10
229940125904 compound 1 Drugs 0.000 description 10
229940125782 compound 2 Drugs 0.000 description 10
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 9
229940124347 antiarthritic drug Drugs 0.000 description 8
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
210000000845 cartilage Anatomy 0.000 description 8
210000002683 foot Anatomy 0.000 description 8
229960004584 methylprednisolone Drugs 0.000 description 8
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 8
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 8
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
229930182558 Sterol Natural products 0.000 description 7
229940121363 anti-inflammatory agent Drugs 0.000 description 7
239000002260 anti-inflammatory agent Substances 0.000 description 7
229910052799 carbon Inorganic materials 0.000 description 7
125000001153 fluoro group Chemical group F* 0.000 description 7
229940121367 non-opioid analgesics Drugs 0.000 description 7
125000003373 pyrazinyl group Chemical group 0.000 description 7
150000003432 sterols Chemical class 0.000 description 7
235000003702 sterols Nutrition 0.000 description 7
210000001258 synovial membrane Anatomy 0.000 description 7
125000003396 thiol group Chemical group [H]S* 0.000 description 7
150000001721 carbon Chemical group 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 6
208000013465 muscle pain Diseases 0.000 description 6
MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
229940005483 opioid analgesics Drugs 0.000 description 6
229960004618 prednisone Drugs 0.000 description 6
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
206010028391 Musculoskeletal Pain Diseases 0.000 description 5
208000030858 Myofascial Pain Syndromes Diseases 0.000 description 5
230000001430 anti-depressive effect Effects 0.000 description 5
230000006378 damage Effects 0.000 description 5
229960000890 hydrocortisone Drugs 0.000 description 5
230000006872 improvement Effects 0.000 description 5
239000000463 material Substances 0.000 description 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
230000002195 synergetic effect Effects 0.000 description 5
238000010998 test method Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
ZOCUOMKMBMEYQV-GSLJADNHSA-N 9alpha-Fluoro-11beta,17alpha,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ZOCUOMKMBMEYQV-GSLJADNHSA-N 0.000 description 4
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
238000009098 adjuvant therapy Methods 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
125000004104 aryloxy group Chemical group 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 4
238000002648 combination therapy Methods 0.000 description 4
229960004397 cyclophosphamide Drugs 0.000 description 4
230000007423 decrease Effects 0.000 description 4
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
229940015508 gabapentin 100 mg Drugs 0.000 description 4
125000005842 heteroatom Chemical group 0.000 description 4
210000000548 hind-foot Anatomy 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
210000003127 knee Anatomy 0.000 description 4
229960000485 methotrexate Drugs 0.000 description 4
OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 4
DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 4
229960004023 minocycline Drugs 0.000 description 4
229960005249 misoprostol Drugs 0.000 description 4
125000002950 monocyclic group Chemical group 0.000 description 4
239000000014 opioid analgesic Substances 0.000 description 4
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000004044 response Effects 0.000 description 4
229960004889 salicylic acid Drugs 0.000 description 4
WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 3
HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 3
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 3
ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 3
TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
208000007848 Alcoholism Diseases 0.000 description 3
229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 3
229940123922 Disease-modifying osteoarthritis drug Drugs 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 3
108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 3
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 3
OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
235000011054 acetic acid Nutrition 0.000 description 3
201000007930 alcohol dependence Diseases 0.000 description 3
125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
229960004238 anakinra Drugs 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000003542 behavioural effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
125000002619 bicyclic group Chemical group 0.000 description 3
229910052797 bismuth Inorganic materials 0.000 description 3
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
229960003677 chloroquine Drugs 0.000 description 3
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
229940111134 coxibs Drugs 0.000 description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 3
229940119740 deoxycorticosterone Drugs 0.000 description 3
CANBGVXYBPOLRR-UHFFFAOYSA-N dimethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(C)C)C1=CC=CS1 CANBGVXYBPOLRR-UHFFFAOYSA-N 0.000 description 3
229950005563 dimethylthiambutene Drugs 0.000 description 3
239000002988 disease modifying antirheumatic drug Substances 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
229960004369 flufenamic acid Drugs 0.000 description 3
LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 3
229950001284 fluprofen Drugs 0.000 description 3
235000013305 food Nutrition 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 3
229960001410 hydromorphone Drugs 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
208000014674 injury Diseases 0.000 description 3
229960000681 leflunomide Drugs 0.000 description 3
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 3
229960000263 levallorphan Drugs 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000010534 mechanism of action Effects 0.000 description 3
229960001293 methylprednisolone acetate Drugs 0.000 description 3
PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 3
229950007471 myrophine Drugs 0.000 description 3
GODGZZGKTZQSAL-VXFFQEMOSA-N myrophine Chemical compound C([C@@H]1[C@@H]2C=C[C@@H]([C@@H]3OC4=C5[C@]23CCN1C)OC(=O)CCCCCCCCCCCCC)C5=CC=C4OCC1=CC=CC=C1 GODGZZGKTZQSAL-VXFFQEMOSA-N 0.000 description 3
125000003544 oxime group Chemical group 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
125000003367 polycyclic group Chemical group 0.000 description 3
229960005205 prednisolone Drugs 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
210000002027 skeletal muscle Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
229960001940 sulfasalazine Drugs 0.000 description 3
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
229960002871 tenoxicam Drugs 0.000 description 3
WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 3
238000005303 weighing Methods 0.000 description 3
RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 2
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 2
VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 description 2
MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 2
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
XTMOQAKCOFLCRZ-UHFFFAOYSA-N (4-acetamidophenyl) 4-nitrooxybutanoate Chemical compound CC(=O)NC1=CC=C(OC(=O)CCCO[N+]([O-])=O)C=C1 XTMOQAKCOFLCRZ-UHFFFAOYSA-N 0.000 description 2
CXAGHAZMQSCAKJ-WAHHBDPQSA-N (4s,7s)-n-[(2r,3s)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepine-4-carboxamide Chemical compound CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@H]1N(C(=O)[C@H](CCC2=O)NC(=O)C=3C4=CC=CC=C4C=CN=3)N2CCC1 CXAGHAZMQSCAKJ-WAHHBDPQSA-N 0.000 description 2
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 description 2
ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 description 2
MYQXHLQMZLTSDB-UHFFFAOYSA-N 2-(2-ethyl-2,3-dihydro-1-benzofuran-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OC(CC)CC2=C1 MYQXHLQMZLTSDB-UHFFFAOYSA-N 0.000 description 2
DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 2
JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 2
WGDADRBTCPGSDG-UHFFFAOYSA-N 2-[[4,5-bis(4-chlorophenyl)-1,3-oxazol-2-yl]sulfanyl]propanoic acid Chemical compound O1C(SC(C)C(O)=O)=NC(C=2C=CC(Cl)=CC=2)=C1C1=CC=C(Cl)C=C1 WGDADRBTCPGSDG-UHFFFAOYSA-N 0.000 description 2
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
JGBUBSOKFSVXKS-LBPRGKRZSA-N 2-methylsulfonylethyl (2s)-2-(6-methoxynaphthalen-2-yl)propanoate Chemical compound C1=C([C@H](C)C(=O)OCCS(C)(=O)=O)C=CC2=CC(OC)=CC=C21 JGBUBSOKFSVXKS-LBPRGKRZSA-N 0.000 description 2
TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 2
SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 2
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
HCJMNOSIAGSZBM-UHFFFAOYSA-N 6-methylsalicylic acid Chemical compound CC1=CC=CC(O)=C1C(O)=O HCJMNOSIAGSZBM-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 2
RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 2
XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 2
SJDDOCKBXFJEJB-MOKWFATOSA-N Belnacasan Chemical compound CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)C=2C=C(Cl)C(N)=CC=2)C(C)(C)C)CCC1 SJDDOCKBXFJEJB-MOKWFATOSA-N 0.000 description 2
241000167854 Bourreria succulenta Species 0.000 description 2
102000055006 Calcitonin Human genes 0.000 description 2
108060001064 Calcitonin Proteins 0.000 description 2
229920001287 Chondroitin sulfate Polymers 0.000 description 2
OIRAEJWYWSAQNG-UHFFFAOYSA-N Clidanac Chemical compound ClC=1C=C2C(C(=O)O)CCC2=CC=1C1CCCCC1 OIRAEJWYWSAQNG-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
BQTXJHAJMDGOFI-NJLPOHDGSA-N Dexamethasone 21-(4-Pyridinecarboxylate) Chemical compound O=C([C@]1(O)[C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)COC(=O)C1=CC=NC=C1 BQTXJHAJMDGOFI-NJLPOHDGSA-N 0.000 description 2
108010008165 Etanercept Proteins 0.000 description 2
UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 2
WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
101100134927 Gallus gallus COR8 gene Proteins 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
FWJKNZONDWOGMI-UHFFFAOYSA-N Metharbital Chemical compound CCC1(CC)C(=O)NC(=O)N(C)C1=O FWJKNZONDWOGMI-UHFFFAOYSA-N 0.000 description 2
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 2
LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
LPMRCCNDNGONCD-RITPCOANSA-N Selfotel Chemical compound OC(=O)[C@@H]1C[C@H](CP(O)(O)=O)CCN1 LPMRCCNDNGONCD-RITPCOANSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010042674 Swelling Diseases 0.000 description 2
108010049264 Teriparatide Proteins 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
210000000683 abdominal cavity Anatomy 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
229960004892 acemetacin Drugs 0.000 description 2
FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 2
238000010306 acid treatment Methods 0.000 description 2
229960002964 adalimumab Drugs 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
238000004378 air conditioning Methods 0.000 description 2
229960005142 alclofenac Drugs 0.000 description 2
ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 2
FJXOGVLKCZQRDN-PHCHRAKRSA-N alclometasone Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O FJXOGVLKCZQRDN-PHCHRAKRSA-N 0.000 description 2
229940062527 alendronate Drugs 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
229960003099 amcinonide Drugs 0.000 description 2
ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 2
229960000212 aminophenazone Drugs 0.000 description 2
229950011249 ampiroxicam Drugs 0.000 description 2
LSNWBKACGXCGAJ-UHFFFAOYSA-N ampiroxicam Chemical compound CN1S(=O)(=O)C2=CC=CC=C2C(OC(C)OC(=O)OCC)=C1C(=O)NC1=CC=CC=N1 LSNWBKACGXCGAJ-UHFFFAOYSA-N 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000001773 anti-convulsant effect Effects 0.000 description 2
229940124599 anti-inflammatory drug Drugs 0.000 description 2
229960003965 antiepileptics Drugs 0.000 description 2
VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 2
FWTXWYXPXGKVJG-UHFFFAOYSA-N atrolactamide Chemical compound NC(=O)C(O)(C)C1=CC=CC=C1 FWTXWYXPXGKVJG-UHFFFAOYSA-N 0.000 description 2
229950011225 atrolactamide Drugs 0.000 description 2
AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 2
229960005207 auranofin Drugs 0.000 description 2
229960001799 aurothioglucose Drugs 0.000 description 2
229960001671 azapropazone Drugs 0.000 description 2
WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
229960002170 azathioprine Drugs 0.000 description 2
230000003796 beauty Effects 0.000 description 2
229960005430 benoxaprofen Drugs 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
229960002537 betamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 2
RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 2
230000010072 bone remodeling Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
229960004272 bucillamine Drugs 0.000 description 2
229950005608 bucloxic acid Drugs 0.000 description 2
IJTPQQVCKPZIMV-UHFFFAOYSA-N bucloxic acid Chemical compound ClC1=CC(C(=O)CCC(=O)O)=CC=C1C1CCCCC1 IJTPQQVCKPZIMV-UHFFFAOYSA-N 0.000 description 2
QTNZYVAMNRDUAD-UHFFFAOYSA-N butacetin Chemical compound CC(=O)NC1=CC=C(OC(C)(C)C)C=C1 QTNZYVAMNRDUAD-UHFFFAOYSA-N 0.000 description 2
229950011189 butacetin Drugs 0.000 description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
229960004015 calcitonin Drugs 0.000 description 2
229960003184 carprofen Drugs 0.000 description 2
IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 2
229960000590 celecoxib Drugs 0.000 description 2
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
235000019693 cherries Nutrition 0.000 description 2
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
229960004630 chlorambucil Drugs 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
210000001612 chondrocyte Anatomy 0.000 description 2
229940059329 chondroitin sulfate Drugs 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
KYXDNECMRLFQMZ-UHFFFAOYSA-N cimicoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=C(Cl)N=CN1C1=CC=C(S(N)(=O)=O)C=C1 KYXDNECMRLFQMZ-UHFFFAOYSA-N 0.000 description 2
229950010851 cimicoxib Drugs 0.000 description 2
GPUVGQIASQNZET-CCEZHUSRSA-N cinnoxicam Chemical compound C=1C=CC=CC=1/C=C/C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 GPUVGQIASQNZET-CCEZHUSRSA-N 0.000 description 2
229950001983 cinnoxicam Drugs 0.000 description 2
229960001653 citalopram Drugs 0.000 description 2
229950010886 clidanac Drugs 0.000 description 2
229960002842 clobetasol Drugs 0.000 description 2
229960004703 clobetasol propionate Drugs 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
229960004544 cortisone Drugs 0.000 description 2
150000001887 cortisones Chemical class 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 2
229960003314 deracoxib Drugs 0.000 description 2
WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 2
229960003662 desonide Drugs 0.000 description 2
WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 2
229960002593 desoximetasone Drugs 0.000 description 2
VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
229960004590 diacerein Drugs 0.000 description 2
229960004154 diflorasone Drugs 0.000 description 2
WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 description 2
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
229960000616 diflunisal Drugs 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
229960003722 doxycycline Drugs 0.000 description 2
XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
229960000403 etanercept Drugs 0.000 description 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
MORSAEFGQPDBKM-UHFFFAOYSA-N ethylmethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(C)CC)C1=CC=CS1 MORSAEFGQPDBKM-UHFFFAOYSA-N 0.000 description 2
229950006111 ethylmethylthiambutene Drugs 0.000 description 2
229960005293 etodolac Drugs 0.000 description 2
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
229960004945 etoricoxib Drugs 0.000 description 2
MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 2
210000003414 extremity Anatomy 0.000 description 2
229960001395 fenbufen Drugs 0.000 description 2
ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 2
229960001419 fenoprofen Drugs 0.000 description 2
229960002679 fentiazac Drugs 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
229960004511 fludroxycortide Drugs 0.000 description 2
229940043075 fluocinolone Drugs 0.000 description 2
229960000785 fluocinonide Drugs 0.000 description 2
NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
229960001048 fluorometholone Drugs 0.000 description 2
FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 2
229960002390 flurbiprofen Drugs 0.000 description 2
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
229960002714 fluticasone Drugs 0.000 description 2
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
229950010931 furofenac Drugs 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
229960002442 glucosamine Drugs 0.000 description 2
229940015045 gold sodium thiomalate Drugs 0.000 description 2
229940115747 halobetasol Drugs 0.000 description 2
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
229960001067 hydrocortisone acetate Drugs 0.000 description 2
XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
229960004171 hydroxychloroquine Drugs 0.000 description 2
229960002927 hydroxychloroquine sulfate Drugs 0.000 description 2
MPGWGYQTRSNGDD-UHFFFAOYSA-N hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 2
229950009183 ibufenac Drugs 0.000 description 2
CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
229960004187 indoprofen Drugs 0.000 description 2
238000011419 induction treatment Methods 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
210000004969 inflammatory cell Anatomy 0.000 description 2
229960000598 infliximab Drugs 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229910052740 iodine Chemical group 0.000 description 2
239000011630 iodine Chemical group 0.000 description 2
229960002844 iprindole Drugs 0.000 description 2
PLIGPBGDXASWPX-UHFFFAOYSA-N iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 description 2
229960002857 isoflupredone Drugs 0.000 description 2
229960003317 isoflupredone acetate Drugs 0.000 description 2
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
229950011455 isoxepac Drugs 0.000 description 2
QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
229960000991 ketoprofen Drugs 0.000 description 2
229960004752 ketorolac Drugs 0.000 description 2
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
UAWXGRJVZSAUSZ-UHFFFAOYSA-N licofelone Chemical compound OC(=O)CC=1N2CC(C)(C)CC2=C(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 UAWXGRJVZSAUSZ-UHFFFAOYSA-N 0.000 description 2
229950003488 licofelone Drugs 0.000 description 2
UGDPYGKWIHHBMB-UHFFFAOYSA-N lobenzarit Chemical compound OC(=O)C1=CC=CC=C1NC1=CC(Cl)=CC=C1C(O)=O UGDPYGKWIHHBMB-UHFFFAOYSA-N 0.000 description 2
229950005662 lobenzarit Drugs 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 2
229960002202 lornoxicam Drugs 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
229960000994 lumiracoxib Drugs 0.000 description 2
KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229960003803 meclofenamic acid Drugs 0.000 description 2
229960003464 mefenamic acid Drugs 0.000 description 2
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
229960000906 mephenytoin Drugs 0.000 description 2
GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
229960002057 metharbital Drugs 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
229960000334 methylprednisolone sodium succinate Drugs 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
OJGQFYYLKNCIJD-UHFFFAOYSA-N miroprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 OJGQFYYLKNCIJD-UHFFFAOYSA-N 0.000 description 2
229950006616 miroprofen Drugs 0.000 description 2
229960001664 mometasone Drugs 0.000 description 2
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 2
230000004660 morphological change Effects 0.000 description 2
BWYBBMQLUKXECQ-GIVPXCGWSA-N n-[(2s)-4-methyl-1-[[(4s,7r)-7-methyl-3-oxo-1-pyridin-2-ylsulfonylazepan-4-yl]amino]-1-oxopentan-2-yl]-1-benzofuran-2-carboxamide Chemical compound N1([C@H](C)CC[C@@H](C(C1)=O)NC(=O)[C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)CC(C)C)S(=O)(=O)C1=CC=CC=N1 BWYBBMQLUKXECQ-GIVPXCGWSA-N 0.000 description 2
HDWWQELUBWGQGA-WMZOPIPTSA-N n-[(2s,4s)-1-(ethoxymethoxy)-5-(hydroxyamino)-4-methyl-5-oxopentan-2-yl]-4-phenoxybenzamide Chemical compound C1=CC(C(=O)N[C@@H](C[C@H](C)C(=O)NO)COCOCC)=CC=C1OC1=CC=CC=C1 HDWWQELUBWGQGA-WMZOPIPTSA-N 0.000 description 2
229960004270 nabumetone Drugs 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
230000002981 neuropathic effect Effects 0.000 description 2
229960000916 niflumic acid Drugs 0.000 description 2
229960000965 nimesulide Drugs 0.000 description 2
HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
235000019391 nitrogen oxide Nutrition 0.000 description 2
230000003040 nociceptive effect Effects 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 2
229960004110 olsalazine Drugs 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
230000003349 osteoarthritic effect Effects 0.000 description 2
229960000649 oxyphenbutazone Drugs 0.000 description 2
HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 2
229960004662 parecoxib Drugs 0.000 description 2
TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 2
229960001639 penicillamine Drugs 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
229960005222 phenazone Drugs 0.000 description 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
229960002895 phenylbutazone Drugs 0.000 description 2
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
229960002702 piroxicam Drugs 0.000 description 2
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 2
229960000851 pirprofen Drugs 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229940014329 polysulfated glycosaminoglycan Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
229950000362 pralnacasan Drugs 0.000 description 2
229960003101 pranoprofen Drugs 0.000 description 2
229960002794 prednicarbate Drugs 0.000 description 2
FNPXMHRZILFCKX-KAJVQRHHSA-N prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 description 2
229960002800 prednisolone acetate Drugs 0.000 description 2
JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 2
229960002943 prednisolone sodium phosphate Drugs 0.000 description 2
229950004597 prednisolone succinate Drugs 0.000 description 2
APGDTXUMTIZLCJ-CGVGKPPMSA-N prednisolone succinate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 APGDTXUMTIZLCJ-CGVGKPPMSA-N 0.000 description 2
229940039040 pregabalin 100 mg Drugs 0.000 description 2
230000008569 process Effects 0.000 description 2
229960002429 proline Drugs 0.000 description 2
OJCPSBCUMRIPFL-UHFFFAOYSA-N prolintane Chemical compound C1CCCN1C(CCC)CC1=CC=CC=C1 OJCPSBCUMRIPFL-UHFFFAOYSA-N 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
229960002466 proquazone Drugs 0.000 description 2
JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 2
229940126409 proton pump inhibitor Drugs 0.000 description 2
239000000612 proton pump inhibitor Substances 0.000 description 2
GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000000552 rheumatic effect Effects 0.000 description 2
201000003068 rheumatic fever Diseases 0.000 description 2
125000006413 ring segment Chemical group 0.000 description 2
229940089617 risedronate Drugs 0.000 description 2
229960004641 rituximab Drugs 0.000 description 2
229960000371 rofecoxib Drugs 0.000 description 2
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
229960000953 salsalate Drugs 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
229950009825 selfotel Drugs 0.000 description 2
UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical class [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
238000004904 shortening Methods 0.000 description 2
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 2
AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
208000037804 stenosis Diseases 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
229950005175 sudoxicam Drugs 0.000 description 2
229960000894 sulindac Drugs 0.000 description 2
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
229910021653 sulphate ion Inorganic materials 0.000 description 2
229960004492 suprofen Drugs 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
229960001603 tamoxifen Drugs 0.000 description 2
229960005460 teriparatide Drugs 0.000 description 2
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 2
230000008719 thickening Effects 0.000 description 2
125000004001 thioalkyl group Chemical group 0.000 description 2
229960001312 tiaprofenic acid Drugs 0.000 description 2
229950002345 tiopinac Drugs 0.000 description 2
229950006150 tioxaprofen Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 2
229960002905 tolfenamic acid Drugs 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
229960005294 triamcinolone Drugs 0.000 description 2
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
229960002117 triamcinolone acetonide Drugs 0.000 description 2
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 2
229960004453 trimethadione Drugs 0.000 description 2
APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
LEHFPXVYPMWYQD-XHIJKXOTSA-N ulobetasol Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]2(C)C[C@@H]1O LEHFPXVYPMWYQD-XHIJKXOTSA-N 0.000 description 2
229960002004 valdecoxib Drugs 0.000 description 2
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
229950007802 zidometacin Drugs 0.000 description 2
229960002791 zimeldine Drugs 0.000 description 2
OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 2
229960004276 zoledronic acid Drugs 0.000 description 2
XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 2
229960003414 zomepirac Drugs 0.000 description 2
VEEHBRVUEHYHQQ-CYBMUJFWSA-N (2r)-2-acetamido-n-benzyl-3-ethoxypropanamide Chemical compound CCOC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VEEHBRVUEHYHQQ-CYBMUJFWSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
125000006083 1-bromoethyl group Chemical group 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
125000006023 1-pentenyl group Chemical group 0.000 description 1
VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
STOVYWBRBMYHPC-KAVGSWPWSA-N 2-[(E)-[(E)-(2-hydroxyphenyl)methylidenehydrazinylidene]methyl]phenol Chemical compound OC1=CC=CC=C1\C=N\N=C\C1=CC=CC=C1O STOVYWBRBMYHPC-KAVGSWPWSA-N 0.000 description 1
XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
NCTCGHLIHJJIBK-UHFFFAOYSA-N 3-phenyl-1,3-oxazolidin-2-one Chemical class O=C1OCCN1C1=CC=CC=C1 NCTCGHLIHJJIBK-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
241001455445 Alfaro Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
241001674044 Blattodea Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920002567 Chondroitin Polymers 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
244000019459 Cynara cardunculus Species 0.000 description 1
235000019106 Cynara scolymus Nutrition 0.000 description 1
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
229930195711 D-Serine Natural products 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102000005915 GABA Receptors Human genes 0.000 description 1
108010005551 GABA Receptors Proteins 0.000 description 1
240000001238 Gaultheria procumbens Species 0.000 description 1
235000007297 Gaultheria procumbens Nutrition 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
HHZQLQREDATOBM-CODXZCKSSA-M Hydrocortisone Sodium Succinate Chemical compound [Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 HHZQLQREDATOBM-CODXZCKSSA-M 0.000 description 1
DLVOSEUFIRPIRM-KAQKJVHQSA-N Hydrocortisone cypionate Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCC1CCCC1 DLVOSEUFIRPIRM-KAQKJVHQSA-N 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
235000006679 Mentha X verticillata Nutrition 0.000 description 1
235000002899 Mentha suaveolens Nutrition 0.000 description 1
235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
208000001505 Musculoskeletal Abnormalities Diseases 0.000 description 1
208000023178 Musculoskeletal disease Diseases 0.000 description 1
206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
241000238367 Mya arenaria Species 0.000 description 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
229940099433 NMDA receptor antagonist Drugs 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
206010030247 Oestrogen deficiency Diseases 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
206010031264 Osteonecrosis Diseases 0.000 description 1
206010033425 Pain in extremity Diseases 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
206010072005 Spinal pain Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
RUJMJVDZRXMDLY-QFDDTMGGSA-N [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] (2s)-2,6-diaminohexanoate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)[C@@H](N)CCCCN)[C@@H]4[C@@H]3CCC2=C1 RUJMJVDZRXMDLY-QFDDTMGGSA-N 0.000 description 1
BXAGUJYMKLFDEM-UHFFFAOYSA-N [N]1C2=CC=C1C=C(N1)C=C(S)C1=CC([N]1)=CC=C1C=C(N1)C=CC1=C2 Chemical compound [N]1C2=CC=C1C=C(N1)C=C(S)C1=CC([N]1)=CC=C1C=C(N1)C=CC1=C2 BXAGUJYMKLFDEM-UHFFFAOYSA-N 0.000 description 1
229960003697 abatacept Drugs 0.000 description 1
YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
229960005164 acesulfame Drugs 0.000 description 1
YFHNDHXQDJQEEE-UHFFFAOYSA-N acetic acid;hydrazine Chemical compound NN.CC(O)=O YFHNDHXQDJQEEE-UHFFFAOYSA-N 0.000 description 1
ASRPLWIDQZYBQK-UHFFFAOYSA-N acetic acid;pentanoic acid Chemical compound CC(O)=O.CCCCC(O)=O ASRPLWIDQZYBQK-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229960000552 alclometasone Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000002723 alicyclic group Chemical group 0.000 description 1
125000000033 alkoxyamino group Chemical group 0.000 description 1
229920000180 alkyd Polymers 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940124277 aminobutyric acid Drugs 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000003502 anti-nociceptive effect Effects 0.000 description 1
229940124346 antiarthritic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 description 1
229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000004982 aromatic amines Chemical class 0.000 description 1
235000016520 artichoke thistle Nutrition 0.000 description 1
210000001188 articular cartilage Anatomy 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000037182 bone density Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
VQNVZLDDLJBKNS-UHFFFAOYSA-N carbamimidoylazanium;bromide Chemical compound Br.NC(N)=N VQNVZLDDLJBKNS-UHFFFAOYSA-N 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000007958 cherry flavor Substances 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
125000004651 chloromethoxy group Chemical group ClCO* 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
230000009194 climbing Effects 0.000 description 1
229960004299 clocortolone Drugs 0.000 description 1
YMTMADLUXIRMGX-RFPWEZLHSA-N clocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O YMTMADLUXIRMGX-RFPWEZLHSA-N 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000011262 co‐therapy Methods 0.000 description 1
125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229960001193 diclofenac sodium Drugs 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
229960001850 droxicam Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
230000000351 effect on allodynia Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
229960001493 etofenamate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003631 expected effect Effects 0.000 description 1
239000004744 fabric Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000005567 fluorenylene group Chemical group 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229940060037 fluorine Drugs 0.000 description 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
210000004744 fore-foot Anatomy 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
229930182478 glucoside Natural products 0.000 description 1
150000008131 glucosides Chemical class 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
229920000591 gum Polymers 0.000 description 1
229960002383 halcinonide Drugs 0.000 description 1
125000004438 haloalkoxy group Chemical group 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
229940083761 high-ceiling diuretics pyrazolone derivative Drugs 0.000 description 1
208000012285 hip pain Diseases 0.000 description 1
230000036732 histological change Effects 0.000 description 1
229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
150000002429 hydrazines Chemical class 0.000 description 1
229960003331 hydrocortisone cypionate Drugs 0.000 description 1
229960001401 hydrocortisone sodium succinate Drugs 0.000 description 1
229950006240 hydrocortisone succinate Drugs 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
QURWXBZNHXJZBE-SKXRKSCCSA-N icatibant Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 QURWXBZNHXJZBE-SKXRKSCCSA-N 0.000 description 1
108700023918 icatibant Proteins 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
210000000281 joint capsule Anatomy 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
210000000629 knee joint Anatomy 0.000 description 1
208000024765 knee pain Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229960003406 levorphanol Drugs 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
229960001929 meloxicam Drugs 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229960001252 methamphetamine Drugs 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
PSCNNGGPKIBAHB-WFVOKNHCSA-N methylprednisolone 21-suleptanic acid ester Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS(O)(=O)=O)CC[C@H]21 PSCNNGGPKIBAHB-WFVOKNHCSA-N 0.000 description 1
229950010796 methylprednisolone suleptanate Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
206010052787 migraine without aura Diseases 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
229930003658 monoterpene Natural products 0.000 description 1
235000002577 monoterpenes Nutrition 0.000 description 1
229960004715 morphine sulfate Drugs 0.000 description 1
GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
208000017445 musculoskeletal system disease Diseases 0.000 description 1
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
OTXAWKXSJDFGID-LMHBHQSJSA-N n-[(2s,3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-(7-hydroxy-2-oxochromen-6-yl)oxyoxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 OTXAWKXSJDFGID-LMHBHQSJSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229960003753 nitric oxide Drugs 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
239000011022 opal Substances 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229910052762 osmium Inorganic materials 0.000 description 1
SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229960002739 oxaprozin Drugs 0.000 description 1
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
230000008058 pain sensation Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229960000761 pemoline Drugs 0.000 description 1
NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical group C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
238000011056 performance test Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000005561 phenanthryl group Chemical group 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000004344 phenylpropyl group Chemical group 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
238000013105 post hoc analysis Methods 0.000 description 1
238000010149 post-hoc-test Methods 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229960002176 prednisolone sodium succinate Drugs 0.000 description 1
FKKAEMQFOIDZNY-CODXZCKSSA-M prednisolone sodium succinate Chemical compound [Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 FKKAEMQFOIDZNY-CODXZCKSSA-M 0.000 description 1
229950008480 prednisolone valerate acetate Drugs 0.000 description 1
DGYSDXLCLKPUBR-SLPNHVECSA-N prednisolone valerate acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O DGYSDXLCLKPUBR-SLPNHVECSA-N 0.000 description 1
BOFKYYWJAOZDPB-FZNHGJLXSA-N prednival Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O BOFKYYWJAOZDPB-FZNHGJLXSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
229960004654 prolintane Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
150000005599 propionic acid derivatives Chemical class 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
150000004040 pyrrolidinones Chemical class 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
229960004622 raloxifene Drugs 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
238000011552 rat model Methods 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
150000003872 salicylic acid derivatives Chemical class 0.000 description 1
230000000276 sedentary effect Effects 0.000 description 1
210000001044 sensory neuron Anatomy 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
208000037959 spinal tumor Diseases 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000005065 subchondral bone plate Anatomy 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
235000011044 succinic acid Nutrition 0.000 description 1
150000003444 succinic acids Chemical class 0.000 description 1
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004354 sulfur functional group Chemical group 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
125000005296 thioaryloxy group Chemical group 0.000 description 1
YFNCATAIYKQPOO-UHFFFAOYSA-N thiophanate Chemical compound CCOC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OCC YFNCATAIYKQPOO-UHFFFAOYSA-N 0.000 description 1
150000003577 thiophenes Chemical class 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
229960001017 tolmetin Drugs 0.000 description 1
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000008733 trauma Effects 0.000 description 1
125000005208 trialkylammonium group Chemical group 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
231100000402 unacceptable toxicity Toxicity 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
239000002699 waste material Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Oncology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW096120539A 2006-06-08 2007-06-07 Therapeutic combination for painful medical conditions TW200814988A (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US81184006P	2006-06-08	2006-06-08
US81185906P	2006-06-08	2006-06-08
PCT/EP2006/008171 WO2007020103A2 (en)	2005-08-18	2006-08-18	Novel use of peptide compounds for treating muscle pain
US11/506,524 US20070043120A1 (en)	2005-08-18	2006-08-18	Therapeutic combination for painful medical conditions
US11/506,578 US20070048372A1 (en)	2005-08-18	2006-08-18	Method for treating non-inflammatory osteoarthritic pain
US11/506,523 US20070197657A1 (en)	2005-08-18	2006-08-18	Method for treating non-inflammatory musculoskeletal pain
US11/506,577 US20070042969A1 (en)	2004-03-26	2006-08-18	Combination therapy for pain in painful diabetic neuropathy

Publications (1)

Publication Number	Publication Date
TW200814988A true TW200814988A (en)	2008-04-01

Family

ID=46964866

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW096120539A TW200814988A (en)	2006-06-08	2007-06-07	Therapeutic combination for painful medical conditions

Country Status (11)

Country	Link
JP (1)	JP2009539792A (de)
KR (1)	KR20090018863A (de)
AR (1)	AR061250A1 (de)
AT (1)	ATE530175T1 (de)
AU (1)	AU2007256352A1 (de)
BR (1)	BRPI0712494A2 (de)
CA (1)	CA2652667A1 (de)
EA (1)	EA200802412A1 (de)
MX (1)	MX2008015341A (de)
TW (1)	TW200814988A (de)
WO (1)	WO2007141018A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200846003A (en) *	2007-03-15	2008-12-01	Astellas Pharma Inc	Novel prophylactic and/or therapeutic agent for diabetic neuropathy
TW200846002A (en) *	2007-03-15	2008-12-01	Astellas Pharma Inc	Novel prophylactic and/or therapeutic agent for diabetic neuropathy
EP2116539A1 (de)	2008-04-25	2009-11-11	Laboratorios Del. Dr. Esteve, S.A.	1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon
CN102149386A (zh) *	2008-09-11	2011-08-10	安斯泰来制药株式会社	伤害感受性疼痛的新型治疗用药物组合物
US8198268B2 (en)	2008-10-31	2012-06-12	Janssen Biotech, Inc.	Tianeptine sulfate salt forms and methods of making and using the same
EP2353598A1 (de)	2010-02-04	2011-08-10	Laboratorios Del. Dr. Esteve, S.A.	Sigma-Liganden zur Anwendung in der Vorbeugung und/oder Behandlung von postoperativem Schmerz
EP2353591A1 (de)	2010-02-04	2011-08-10	Laboratorios Del. Dr. Esteve, S.A.	Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon
EP2388005A1 (de)	2010-05-21	2011-11-23	Laboratorios Del. Dr. Esteve, S.A.	Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie
AU2011267474B2 (en)	2010-06-15	2016-05-26	Grünenthal GmbH	Pharmaceutical combination for the treatment of pain
EP2415471A1 (de)	2010-08-03	2012-02-08	Laboratorios Del. Dr. Esteve, S.A.	Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie
EP2524694A1 (de)	2011-05-19	2012-11-21	Laboratorios Del. Dr. Esteve, S.A.	Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes
CA2888647A1 (en)	2012-11-20	2014-05-30	Revive Therapeutics Inc.	The use of bucillamine in the treatment of gout
US9662305B2 (en)	2012-11-20	2017-05-30	Revive Therapeutics Inc.	Use of bucillamine in the treatment of gout
SG11201604480PA (en)	2013-12-17	2016-07-28	Esteve Labor Dr	SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
EP3824906A1 (de)	2016-12-21	2021-05-26	Amgen Inc.	Anti-tnf alpha antikörperformulierungen
WO2022194198A1 (zh) *	2021-03-17	2022-09-22	上海博志研新药物技术有限公司	一种拉考沙胺药物组合物、其制备方法及应用
CN114306346A (zh) *	2021-12-14	2022-04-12	四川大学华西医院	拉莫三嗪在治疗系统性红斑狼疮中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE327744T1 (de) *	2001-03-20	2006-06-15	Sanol Arznei Schwarz Gmbh	Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
US7794987B2 (en) *	2003-12-02	2010-09-14	Ucb Pharma Gmbh	Method for treating central neuropathic pain
EP1579858A1 (de) *	2004-03-26	2005-09-28	Schwarz Pharma Ag	Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
KR20070007931A (ko) *	2004-04-16	2007-01-16	쉬바르츠파르마에이지	만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
MXPA06012685A (es) *	2004-05-03	2007-01-16	Univ Duke	Composiciones para afectar la perdida de peso.

2007
- 2007-06-06 CA CA002652667A patent/CA2652667A1/en not_active Abandoned
- 2007-06-06 WO PCT/EP2007/005036 patent/WO2007141018A1/en not_active Ceased
- 2007-06-06 AT AT07725884T patent/ATE530175T1/de not_active IP Right Cessation
- 2007-06-06 AR ARP070102440A patent/AR061250A1/es not_active Application Discontinuation
- 2007-06-06 AU AU2007256352A patent/AU2007256352A1/en not_active Abandoned
- 2007-06-06 KR KR1020097000247A patent/KR20090018863A/ko not_active Withdrawn
- 2007-06-06 BR BRPI0712494-5A patent/BRPI0712494A2/pt not_active IP Right Cessation
- 2007-06-06 EA EA200802412A patent/EA200802412A1/ru unknown
- 2007-06-06 MX MX2008015341A patent/MX2008015341A/es unknown
- 2007-06-06 JP JP2009513597A patent/JP2009539792A/ja active Pending
- 2007-06-07 TW TW096120539A patent/TW200814988A/zh unknown

Also Published As

Publication number	Publication date
WO2007141018A1 (en)	2007-12-13
AR061250A1 (es)	2008-08-13
BRPI0712494A2 (pt)	2012-10-09
AU2007256352A1 (en)	2007-12-13
EA200802412A1 (ru)	2009-06-30
CA2652667A1 (en)	2007-12-13
ATE530175T1 (de)	2011-11-15
JP2009539792A (ja)	2009-11-19
KR20090018863A (ko)	2009-02-23
MX2008015341A (es)	2009-02-10

Publication	Publication Date	Title
US20120225119A1 (en)	2012-09-06	Therapeutic combination for painful medical conditions
EP1915140B1 (de)	2011-11-23	Neue verwendung von peptid-verbindungen zur behandlung von muskelschmerzen
AU2007256352A1 (en)	2007-12-13	Therapeutic combination for painful medical conditions
US20070042969A1 (en)	2007-02-22	Combination therapy for pain in painful diabetic neuropathy
US20070048372A1 (en)	2007-03-01	Method for treating non-inflammatory osteoarthritic pain
US20100256179A1 (en)	2010-10-07	Combination therapy for pain in painful diabetic neuropathy
TWI392670B (zh)	2013-04-11	經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
AU782759B2 (en)	2005-08-25	Composition comprising a tramadol material and an anticonvulsant drug
JP5087629B2 (ja)	2012-12-05	フェニルプロピオンアミド化合物およびそれらの使用
EP2205231A1 (de)	2010-07-14	Pharmazeutische zusammensetzungen von 5-hydroxytryptophan und einer serotonin-verstärkenden verbindung
TWI361693B (en)	2012-04-11	Novel use of peptide compounds for treating essential tremor and other tremor syndromes
EP3062791B1 (de)	2020-01-08	Neuartige behandlung gegen aufmerksamkeits- und kognitionsstörungen und gegen mit neurodegenerativen erkrankungen assoziierte demenz
EA012173B1 (ru)	2009-08-28	Сочетание аналептина модафинила и антидепрессанта для лечения депрессии
JP2012508186A (ja)	2012-04-05	むずむず脚症候群および睡眠障害の治療
CN101484152A (zh)	2009-07-15	用于疼痛性医学病症的治疗组合
EP2026788B1 (de)	2011-10-26	Therapeutische kombination für schmerzhafte medizinische zustände
US6335372B1 (en)	2002-01-01	Treatment of obsessive compulsive disorder
KR20060072127A (ko)	2006-06-27	세로토닌 재흡수 억제제 및 록사핀의 조합
KR20080038408A (ko)	2008-05-06	근육통 치료를 위한 펩티드 화합물의 신규한 용도
HK40007948A (en)	2020-06-05	Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
KR20060072126A (ko)	2006-06-27	세로토닌 재흡수 억제제 및 아목사핀의 조합
CN101171011A (zh)	2008-04-30	用于治疗食欲紊乱的含有1-(3-氯苯基)-3-烷基哌嗪的药物组合物